Anti-Human CD117 Antibodies Mediate Clearance of Myelodysplastic Syndrome Hematopoietic Stem Cells and Facilitate Establishment of Normal Hematopoiesis in Transplantation

Myelodysplastic syndrome (MDS) is an aging-associated group of clonal disorders characterized by ineffective hematopoiesis, leading to cytopenias and an increased risk of developing acute myeloid leukemia (AML). MDS arises from abnormal hematopoietic stem cells (HSCs). The only potentially curative therapy available for MDS patients is hematopoietic cell transplantation (HCT), but relapse is common, likely due to the inability of current therapies to effectively eliminate disease-initiating MDS HSCs.

Source: Biology of Blood and Marrow Transplantation - February 1, 2018 Category: Hematology Authors: Wendy W. Pang, Agnieszka Czechowicz, Jessica Poyser, Christopher Y. Park, Irving L. Weissman, Judith A. Shizuru Source Type: research